The Power List 2022 will focus on the top 10 VIPs in three key categories of medicine making
Why does the full potential of biosimilars remain untapped? Four experts weigh in.
The latest business news and views in pharma.
Why is the pharma industry overly reluctant to accept new ideas?
FDA Commissioner Scott Gottlieb wants more biosimilars on the US market.
Sitting Down With… Richard Markus, Vice President of Global Development, Amgen, USA
EMA relocation, a price-fixing scandal, and FDA warning letters… What's new for pharma in business?
Sitting Down With… Abhijit Mukherjee, COO of Dr. Reddy's Laboratories, India
Why stop at biosimilar when you can be biobetter?
The FDA aims to reduce drug prices with a more competitive market - and generics are key.
John Lambert talks antibody-drug conjugates and his involvement with Kadcyla.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.
Blue Light for Waste Reduction
The Innovation Awards 2021
The Cobalt-60 Pioneers